Combination Chemotherapy for Lung Cancer
Author Information
Author(s): Seto T, Yoh K, Asoh H, Yamamoto H, Semba H, Ichinose Y
Hypothesis
Can the combination of gemcitabine and oral UFT improve treatment outcomes for patients with advanced non-small cell lung cancer?
Conclusion
The combination chemotherapy of UFT and gemcitabine was well tolerated and resulted in a 33% response rate in patients with advanced non-small cell lung cancer.
Supporting Evidence
- Eight out of 24 patients achieved a partial response to the treatment.
- The most appropriate dosing option was determined to be 400 mg/m2 of UFT for 14 days with 900 mg/m2 of gemcitabine on days 8 and 15.
- The overall response rate was 33%, with a higher rate of 45% among chemo-naïve patients.
Takeaway
This study tested a new combination of two cancer drugs to see if they could help people with a type of lung cancer. It found that the treatment worked for some patients and was safe to use.
Methodology
Patients received oral UFT and gemcitabine in a phased dosing schedule to determine the optimal treatment regimen.
Limitations
The study was limited by its small sample size and the phase I design, which primarily focused on safety and dosage rather than efficacy.
Participant Demographics
The study included 24 patients, 16 men and 8 women, with a median age of 72 years.
Statistical Information
Confidence Interval
95% confidence interval: 14 to 52%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website